Triple-negative breast cancer (TNBC) is an aggressive form of the disease that accounts for 15% of all breast cancer cases.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer ...
6don MSN
Women whose breast cancers need estrogen to grow are often treated for five or more years with medications to lower estrogen ...
Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.
(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...
Medical Xpress on MSN6d
Breast cancer treatment advances with light-activated ‘smart bomb’It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Dutch health insurers have stopped fully covering two of three medicines for metastatic hormonal breast cancer. Since January ...
Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...
Nearly 22% of the millions of grant dollars given to UT Southwestern Medical Center by the National Institute of Health could be threatened.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results